Here are 1-3 brief analogies for Korsana Biosciences (KRSA):

• It's like an early-stage Biogen, focused on CNS diseases but with all its drug candidates still in clinical trials.

• Imagine a nascent Vertex Pharmaceuticals, but specializing in sGC stimulator drugs for a range of serious conditions.

• CY6463: A CNS-penetrant, soluble guanylate cyclase (sGC) stimulator currently in clinical trials for conditions such as mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, Alzheimer's disease with vascular pathology, and schizophrenia.
• Praliciguat: An orally administered systemic sGC stimulator undergoing Phase II studies for resistant hypertension and diabetic nephropathy.
• Olinciguat: An orally administered vascular sGC stimulator in Phase II studies for the treatment of sickle cell disease.
• CY3018: A development candidate aimed at treating various disorders of the central nervous system (CNS).

Korsana Biosciences (KRSA) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of medicines. As such, it does not sell finished products directly to individual consumers or the general public.

Instead, Korsana Biosciences primarily engages in partnerships and licensing agreements with other pharmaceutical companies for the further development, manufacturing, and commercialization of its drug candidates.

Based on the provided information, Korsana Biosciences has a major licensing agreement with:

• Akebia Therapeutics, Inc. (AKEB)

Akebia Therapeutics, Inc. is a key partner involved in the development, manufacture, medical affairs, and commercialization of pharmaceutical products under this agreement, and therefore serves as a major "customer" in the context of Korsana's business model.

Akebia Therapeutics, Inc. (AKBA)

The primary risks for Korsana Biosciences (KRSA) are centered around its position as a clinical-stage biopharmaceutical company focused on neurodegenerative diseases.

1. Clinical Trial and Regulatory Risk: Korsana Biosciences' success is heavily dependent on the successful clinical development and regulatory approval of its lead drug candidate, KRSA-028, for Alzheimer's disease, as well as any future pipeline candidates. The company expects Phase 1 healthy volunteer data in mid-2027 and interim proof-of-concept data in Alzheimer's patients by year-end 2027 or Q1 2028. Clinical trials are inherently uncertain, and there is no guarantee that KRSA-028 will demonstrate sufficient efficacy or safety to progress through all trial phases or receive necessary regulatory approvals.

2. Competition in Alzheimer's Disease Treatment: The Alzheimer's disease therapeutic landscape is highly competitive, with existing approved treatments and numerous other companies actively developing new therapies. KRSA-028 is an investigational shuttled monoclonal antibody targeting amyloid beta, a mechanism for which other anti-amyloid antibodies are already approved. Korsana will need to differentiate KRSA-028 and its proprietary Therapeutic Targeting (THETA™) platform effectively to compete for market share if it achieves approval.

3. Intellectual Property and Platform Risk: Korsana's business model relies significantly on its proprietary Therapeutic Targeting (THETA™) platform, designed to enhance central nervous system (CNS) exposure of therapies. The company's ability to protect its intellectual property related to this platform and its drug candidates through patents and other means is crucial. Any challenges to its patents, or the emergence of more effective or safer competing technologies, could significantly undermine the value of its platform and pipeline.

Korsana Biosciences (symbol: KRSA) primarily focuses on developing therapeutics for neurodegenerative diseases, with its lead product candidate, KRSA-028, targeting Alzheimer's disease.

The addressable market for Alzheimer's disease treatments is substantial and projected to grow significantly:

• The global Alzheimer's therapeutics market size was approximately 6.49 billion USD in 2025. It is predicted to increase from 7.79 billion USD in 2026 to approximately 38.61 billion USD by 2035, growing at a Compound Annual Growth Rate (CAGR) of 19.52% from 2026 to 2035. Other estimates place the global market at around 5.038 billion USD in 2025, with a projected CAGR of 23.7% from 2020 to 2034. Another report estimated the market at 5.7 billion USD in 2025, reaching 13.13 billion USD by 2035 with an 8.7% CAGR from 2026 to 2035.
• For the United States, which is a dominant region in the global market, the Alzheimer's drugs market size was valued at 3.4 billion USD in 2025. This market is expected to reach 5.8 billion USD by 2034, demonstrating a CAGR of 6.04% during the period of 2026-2034. North America held the largest share of the global Alzheimer's therapeutics market, accounting for 46.10% in 2025, and 51.55% of the Alzheimer's drugs market in 2025, with a valuation of 2.10 billion USD in 2025, projected to reach 2.21 billion USD in 2026.

Korsana Biosciences (KRSA) expects its future revenue growth over the next 2-3 years to be primarily driven by the following factors:

1. Advancement and potential commercialization of KRSA-028 for Alzheimer's disease: The company's lead asset, KRSA-028, is an investigational shuttled monoclonal antibody targeting amyloid beta for Alzheimer's disease. Key milestones anticipated within this timeframe include Phase I healthy volunteer data in mid-2027 and interim proof-of-concept data measuring amyloid plaque clearance in Alzheimer's patients by year-end 2027 or Q1 2028. Successful clinical development, regulatory approval, and subsequent market launch of this therapy would be a significant driver of revenue.
2. Expansion of the pipeline leveraging the Therapeutic Targeting (THETA™) platform: Korsana Biosciences is focused on discovering and developing novel therapies for neurodegenerative diseases using its proprietary Therapeutic Targeting (THETA™) platform. The company is actively building a broader pipeline to address other neurodegenerative disorders by utilizing this technology. The successful development and eventual commercialization of these new drug candidates would create additional revenue streams.
3. Strategic partnerships and licensing agreements: As a clinical-stage biotechnology company, Korsana Biosciences could generate future revenue through strategic partnerships or licensing agreements related to its lead asset, KRSA-028, or its proprietary THETA™ platform. Such collaborations can provide upfront payments, milestone payments upon achieving certain development or regulatory benchmarks, and royalties on future product sales.

Share Issuance

• Prior to the merger closing on September 8, 2026, Cyclerion Therapeutics' common stock underwent a 1-for-7 reverse split, reducing its outstanding shares from approximately 4.7 million to about 0.7 million.
• In conjunction with the merger, Cyclerion shareholders approved an increase in the authorized common shares from 400,000,000 to 700,000,000.
• Following the merger, pre-merger Cyclerion shareholders own approximately 1.5% of the combined company, while pre-merger Korsana stockholders hold about 98.5%.

Inbound Investments

• Korsana Biosciences completed a private placement of $380 million in gross proceeds immediately prior to the merger with Cyclerion Therapeutics.
• This $380 million financing included common stock and pre-funded warrants and was led by Fairmount and Venrock Healthcare Capital Partners, with participation from numerous other investors.
• When Korsana Biosciences emerged from stealth in February 2026, it announced $175 million in funding, comprising a $25 million seed investment in 2024 and a $150 million Series A financing round in September 2025.

Outbound Investments

• Korsana Biosciences has not made any reported investments or acquisitions as of June 2026.

Capital Expenditures

• Cyclerion Therapeutics reported capital expenditures of approximately -$0.066 million in the most recent quarter.
• Over the last 12 months, Cyclerion Therapeutics' capital expenditures amounted to approximately -$0.07 million.